Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment
Status:
Terminated
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
This study will measure the oral bioavailability and pharmacokinetics of known bioactive
compounds from a standardized Centella asiatica water extract product (CAP) in mildly
demented elders on cholinesterase inhibitor therapy. Compound levels will be measured in
human plasma and urine over 12 hours after acute oral administration of two doses of the
botanical extract product. The dose giving maximum plasma levels (Cmax)closest to those
observed in the investigator's mouse studies, the area under the curve (AUC0-12), as well as
the rate of clearance (t ½) of the known compounds and time of maximum concentration (tmax),
will be identified. These data will be used to inform decisions on the dosage and dosing
frequency for future clinical trials.
Phase:
Early Phase 1
Details
Lead Sponsor:
Oregon Health and Science University
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)